{"filings":[{"id":93099,"accession_number":"0001628280-26-028852","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health Q1 2026 net income $46.8M, diluted EPS $6.52, revenue $216.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $216.5M (+2.2% YoY); hospital division revenue $207.6M.","Net income attributable to Nutex $46.8M (diluted EPS $6.52) vs $21.2M ($3.33) YoY.","Adjusted EBITDA $57.6M vs $72.8M YoY; operating cash flow $75.5M.","Board approved self-development of hospital facilities; plans 3-5 hospitals/year.","Cash $207.3M record high; long-term debt net $24.3M down from $29.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":6.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":216485000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93098,"accession_number":"0001628280-26-026828","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nutex Health annual meeting elects all 7 directors, approves say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; Thomas T. Vo received 2,554,009 votes 'for' and 89,198 withheld.","Advisory vote on executive compensation approved: 2,505,375 for, 126,612 against, 11,220 abstain.","Grant Thornton LLP ratified as auditor for FY 2026: 3,841,817 for, 25,441 against, 32,917 abstain.","Approximately 69.29% of eligible shares voted; broker non-votes of 1,256,968 on director and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104439,"accession_number":"0001628280-26-015174","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health FY2025 revenue up 82% to $875M, diluted EPS $10.48; announces $25M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $875.3M, up 82.4% YoY; net income $70.8M vs $52.1M; diluted EPS $10.48 vs $9.69.","Q4 revenue $151.7M (-41.1% YoY) due to $55M arbitration true-up and $69M arbitration revenue recorded in Q4 2024.","Q4 net income $11.8M vs $61.6M; EBITDA $25.7M vs $78.9M; Adjusted EBITDA $16.6M vs $86.7M.","Board authorized $25M stock repurchase program over 6 months to offset dilution from earn-out shares for hospitals.","Remediated all previously disclosed material weaknesses in internal controls over financial reporting in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120738,"accession_number":"0001628280-25-053849","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nutex Health files auditor consent to incorporate 2023 audit report by reference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP consent to incorporate Dec 31, 2023 audit report into registration statements.","Audit report was previously included in Form 10-K/A filed Nov 18, 2025.","Consent enables reference to 2023 financials in future securities filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120737,"accession_number":"0001628280-25-053170","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health Q3 2025 revenue $267.8M (+240% YoY), net income $55.4M vs loss $8.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $267.8M for Q3 2025, up 240% YoY; hospital division revenue $260.2M, up 263% YoY.","Net income attributable to Nutex of $55.4M in Q3 2025 vs net loss of $8.8M in Q3 2024; diluted EPS $7.76.","Adjusted EBITDA attributable to Nutex of $98.5M in Q3 2025 vs $9.7M in Q3 2024.","YTD 2025: revenue $723.6M (+225%), net income $59.0M vs loss $9.5M, adjusted EBITDA $243.0M.","Regained Nasdaq compliance on Nov 19, 2025 after filing delinquent 10-Q; matter closed."],"consensus_eps_estimate":null,"consensus_eps_actual":8.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":723578000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120736,"accession_number":"0001628280-25-052962","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health H1 2025 revenue $455.8M (+217.5% YoY), net income $3.5M, launches $25M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["H1 2025 revenue $455.8M (+217.5% YoY); net income $3.5M vs net loss $0.7M in H1 2024.","Diluted EPS $0.55 (H1 2025) vs $(0.15); Adjusted EBITDA $144.4M vs $6.4M YoY.","Q2 2025 revenue $244.0M (+220.7% YoY); net loss $17.7M includes $78.7M non-cash stock-based comp.","Board authorized $25M stock repurchase program on Aug 14, 2025 to offset dilution.","Net cash from operations $78.2M H1; cash balance $96.7M at June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":8.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":723578000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120735,"accession_number":"0001628280-25-052952","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health restates Q1 2025: revenue $211.8M, net income $21.2M, diluted EPS $3.33","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $211.8M, up 214% YoY from $67.5M.","Net income attributable to Nutex $21.2M vs net loss $0.4M in Q1 2024.","Diluted EPS $3.33 vs loss per share $0.08.","Adjusted EBITDA $72.8M vs $(0.4)M prior year.","Net cash from operating activities of $51.0M for Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":8.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":723578000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120734,"accession_number":"0001628280-25-052898","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health restates 2024 results: revenue $479.9M (+93.8% YoY), net income $52.1M vs loss $45.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Restated full-year 2024: revenue $479.9M (up 93.8% YoY); net income $52.1M vs net loss $45.8M in 2023.","Diluted EPS $9.69 vs diluted loss per share $10.39 in 2023; adjusted EBITDA $124.1M (up 1,046% YoY).","Restatement adjustments: non-cash reclassifications increased liabilities $13.4M, decreased equity similarly; net income lowered ~$0.5M.","Q4 2024 revenue $257.6M (+269.8% YoY); net income $61.6M vs net loss $31.6M in Q4 2023.","Company notes stock repurchase program and arbitration process as ongoing; cash balance $40.6M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":8.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":723578000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120733,"accession_number":"0001479681-25-000085","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"Nutex Health Q3 prelim: cash collections up 259% YoY, patient volume +11.1%; Nasdaq extension granted","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q3 2025 patient volume of 46,293 visits, up 11.1% vs Q3 2024.","Cash collections for Q3 2025 surged 258.8% to $235M, driven by revenue cycle improvements.","YTD 2025 cash collections $546M, up 176.9% vs YTD 2024; patient volume +14% to 140,135.","Nasdaq extended deadline to Dec 12, 2025, for filing delinquent Q2 2025 10-Q.","Company warns preliminary metrics are unaudited and subject to change upon final review."],"consensus_eps_estimate":null,"consensus_eps_actual":8.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":723578000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137325,"accession_number":"0001479681-25-000083","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nutex Health appoints Wesley Bamburg as COO effective Oct 13, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wesley Bamburg, former COO at HCA Houston Healthcare North Cypress, appointed COO effective October 13, 2025.","Two-year employment agreement with base salary of $415,000, signing bonus of $100,000 (quarterly installments), and bonus up to 60% of base.","Bamburg replaces Joshua DeTillio, whose departure was disclosed in a July 2025 8-K.","Bamburg brings 20 years of healthcare operations experience from HCA and prior payor/provider roles across 11 states."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137324,"accession_number":"0001479681-25-000077","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Derivative lawsuit filed against Nutex Health executives and board alleging violations and mismanagement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Plaintiff Juan Camilo Jimenez filed derivative action in S.D. Texas (Case 4:25-cv-04253) on Sept 8, 2025.","Defendants include CEO, CFO, President, all current directors (except Jaumot), and a retired director.","Claims include violations of Sec 14(a) of Exchange Act, breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste.","Seeks unspecified damages, restitution, and corporate governance reforms; company cannot predict outcome or estimate impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137323,"accession_number":"0001479681-25-000072","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nutex Health appoints Michael L. Reed as Lead Independent Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael L. Reed appointed Lead Independent Director effective Sept 2, 2025.","Reed has served on Nutex Health board since April 2022; member of Audit, Compensation, and Nominating/Governance committees.","Role includes presiding over independent director sessions and serving as liaison between board and management.","Reed will receive additional compensation per company's director compensation program as disclosed in June 2025 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137322,"accession_number":"0001479681-25-000070","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Securities class action lawsuit filed against Nutex Health tracking short seller report","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Putative class action filed Aug 22, 2025 in SD Texas (Case 4:25-cv-03999) claiming Sections 10(b) and 20(a) violations.","Suit names Company as well as CEO, CFO, and President; allegations track a recent short seller report.","Plaintiff seeks unspecified damages; Company disputes allegations and vows to vigorously defend.","Company cannot estimate potential impact but warns adverse ruling could materially affect financial position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137321,"accession_number":"0001479681-25-000068","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["2.02","3.01","4.02","8.01","9.01"],"status":"ready","headline":"Nutex Health restates FY2024 and Q1 2025; receives Nasdaq delisting notice for late filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restatement due to misclassification of obligations for under-construction hospitals; liabilities increase $10-20M (Dec 2024) and $20-50M (Mar 2025); equity decreases correspondingly.","Material weakness in internal controls identified; company engaging accounting firm for remediation.","Nasdaq notice for late filing of Q2 2025 10-Q; 60 days to file or submit compliance plan.","Short seller report on July 22, 2025 caused stock drop of 16.5%; company disputes allegations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137320,"accession_number":"0001479681-25-000058","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health reports Q2 prelim revenue $244M (+221% YoY); announces $25M buyback, delays 10-Q","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 total revenue $244.0M, up 220.7% from $76.1M in Q2 2024; gross profit $124.9M (51.2% margin) vs $22.6M (29.7%).","Hospital visits 45,573 (+10.6% YoY); mature hospital visits up 0.6%.","Delays 10-Q filing due to non-cash accounting adjustments for stock-based compensation on under-construction hospitals; expects to file within 5-day grace period.","Board authorizes stock repurchase program of up to $25.0M over six months, to commence after 10-Q filing, to offset dilution from stock compensation.","Cancels previously scheduled August 15 conference call; will reschedule."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":455774000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137319,"accession_number":"0001628280-25-035002","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nutex Health shareholders approve director elections, equity plan amendment at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; top vote-getter Frank Jaumot with 2,798,958 for, lowest Michael Reed with 2,253,524 for.","Advisory say-on-pay approved with 2,556,545 votes for and 226,342 against.","Equity plan amendment to increase shares by 1.1M and add 5% annual evergreen passed (2,075,665 for, 723,697 against).","Grant Thornton LLP ratified as independent auditor for FY2025 with 3,833,735 votes for.","Approximately 71% of eligible shares voted (3,916,269 of 5,555,116); 1,116,664 broker non-votes on most items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137318,"accession_number":"0001628280-25-034795","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nutex Health COO Joshua DeTillio resigns effective Aug 8, 2025 to become CEO elsewhere","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joshua DeTillio notified Nutex Health of his resignation as COO effective August 8, 2025.","Resignation is to assume a CEO position at another company; not due to any dispute with the Company.","Board of Directors has initiated a search for a replacement candidate.","No disagreements with operations, policies, or practices cited.","Transition expected to be orderly with full notice period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154638,"accession_number":"0001479681-25-000028","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Nutex Health dismisses CBIZ as auditor, appoints Grant Thornton; material weaknesses cited","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit committee dismissed CBIZ CPAs P.C. effective May 15, 2025; CBIZ did not issue an audit report.","Grant Thornton LLP appointed as independent auditor for fiscal year ending Dec 31, 2025, effective May 15, 2025.","Material weaknesses in internal control over financial reporting disclosed, including IT access, change management, and segregation of duties.","Weaknesses previously reported in April 25, 2025 8-K; no other reportable events during interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154637,"accession_number":"0001479681-25-000024","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health Q1 revenue surges 214% to $211.8M; net income $14.6M vs loss $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS $2.56 vs ($0.08) in Q1 2024; EBITDA $43.1M (+507% YoY).","Arbitration process added ~$105M in revenue, 73% of total revenue increase.","Stock-based compensation $36.1M (non-cash, one-time) weighed on GAAP net income.","Cash from operations $51.0M; cash balance $87.7M, long-term debt $21.7M.","Hospital visits up 20.5% YoY; mature hospitals revenue rose 186.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":211789000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154636,"accession_number":"0001479681-25-000011","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Auditor Marcum LLP resigns; Nutex Health discloses material weaknesses, hires CBIZ","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor on April 25, 2025, due to acquisition by CBIZ CPAs P.C.","No disagreements with Marcum on accounting principles or audit scope during fiscal 2023-2024.","Material weaknesses reported: ineffective IT access controls, program change mgmt, vendor mgmt, segregation of duties, and spreadsheet controls.","CBIZ CPAs P.C. engaged as new independent registered public accounting firm for FY 2025.","No prior consultations between Nutex and CBIZ on accounting or auditing matters before engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173163,"accession_number":"0001479681-25-000008","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health reports FY 2024 net income of $52.2M vs loss of $45.8M in 2023; revenue up 93.8% to $479.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 total revenue $479.9M (+93.8% YoY); net income $52.2M vs net loss $45.8M in 2023.","Diluted EPS $9.71 vs $(10.39); Adjusted EBITDA $123.7M up 1,045% from $10.8M.","Arbitration process added $169.7M more revenue in 2024 than 2023; drove 73.1% of revenue growth.","Q4 2024 revenue $257.6M (+270% YoY); operating income $114.2M vs operating loss $26.1M.","Cash from ops $23.2M; total assets $655.3M; long-term debt $22.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":211789000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173162,"accession_number":"0001079973-25-000190","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nutex Health reports >80% arbitration success rate in Q4 2024 under No Surprises Act","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Since July 2024, Nutex submits 60-70% of billable visits to arbitration monthly.","Arbitration success rate exceeded 80% in Q4 2024.","Company beginning to realize cash impact of arbitration; expects to recover substantial underpaid amounts.","Costs include fees for third-party providers and dispute resolution entities, paid upfront.","Cautions future success may not continue due to regulatory changes or payer responses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190192,"accession_number":"0001479681-24-000016","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health Q3: Revenue $78.8M (+26%), Adj EBITDA $13.5M (+938%), Operating income positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $78.8M vs $62.7M YoY (+26%); mature hospitals grew 20.7%.","Operating income $9.7M vs loss of $0.8M; includes $2.0M non-cash stock comp.","Adjusted EBITDA attributable to Nutex $13.5M vs $1.3M (+938% YoY).","Net loss attributable $8.8M (incl. $6.7M non-cash warrant loss) vs $5.5M loss.","Hospital visits 41,668 (+11.3%); nine-month operating cash flow $23.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":222330917.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206696,"accession_number":"0001479681-24-000008","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health Q2 revenue up 29% to $76.1M; Adjusted EBITDA up 200% to $12.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Nutex of $0.4M vs $3.5M loss in Q2 2023; H1 net loss $0.7M vs $8.6M.","Hospital division visits 41,208 in Q2 (+28% YoY); mature hospital revenue +13.2%.","Adjusted EBITDA (attributable) $12.0M in Q2, up 200% YoY; H1 Adjusted EBITDA $16.6M (+159%).","Operating cash flow of $16.3M in H1 2024; cash $40.8M, long-term debt $22.4M.","Non-cash impairments of $3.5M assets and $3.2M goodwill; $3.1M gain on warrant liability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":143536048.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206695,"accession_number":"0001079973-24-001100","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nutex Health regains Nasdaq minimum bid price compliance after reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received compliance notice from Nasdaq on July 24, 2024.","Reverse stock split (1:10) effective July 3, 2024 lifted bid price above $1.00.","Closing bid price remained above $1.00 from July 3 through July 23, 2024.","Nasdaq Hearing Panel determined to continue listing of common stock (NUTX).","Matter closed; company avoids delisting risk under Rule 5550(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206694,"accession_number":"0001553350-24-000058","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Nutex Health effects 1-for-10 reverse stock split effective July 2, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-10 reverse stock split; filed July 1, effective 11:59 pm ET July 2, 2024.","Previous 1-for-15 split effective April 10, 2024; cumulative ratio 1-for-150 from pre-April shares.","No fractional shares; stockholders entitled to fractional shares receive one whole share.","Authorized shares unchanged at 950M; trading symbol NUTX; new CUSIP 67079U306.","Stock began trading on Nasdaq on post-split basis July 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223891,"accession_number":"0001079973-24-000910","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["3.01","5.07","9.01"],"status":"ready","headline":"Nutex Health receives Nasdaq exception until July 22 to effect reverse stock split and regain $1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted Nutex exception until July 22, 2024 to execute reverse split and regain $1.00 minimum bid.","Stockholders approved reverse stock split (1-for-2 to 1-for-16); board to set exact ratio within one year.","Company had already done a 1-for-15 reverse split in April 2024 but still not compliant; delisting if not cured by July 22.","Annual meeting also elected all director nominees, approved executive compensation, and ratified Marcum LLP as auditor for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223890,"accession_number":"0001479681-24-000005","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nutex Health receives Nasdaq delisting notice for bid price non-compliance; appeals, hearing July 9","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Nutex that it failed to regain the $1.00 minimum bid price by May 20, 2024.","Company requested an appeal hearing before Nasdaq Hearings Panel, staying delisting; hearing set for July 9, 2024.","Board approved a reverse stock split (1:2 to 1:16) subject to shareholder vote at June 17, 2024 Annual Meeting.","If appeal fails and compliance not regained, common stock could be suspended from Nasdaq trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223889,"accession_number":"0001558370-24-007416","cik":1479681,"company_name":"Nutex Health Inc.","ticker":"NUTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nutex Health Q1 2024 revenue $67.5M (+20% YoY); net loss narrows to $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $67.5M vs $56.3M YoY; hospital visits up 21.1% to 40,068.","Hospital division operating income rose 119% to $10.5M; overall operating income $1.5M vs loss of $4.5M.","Adjusted EBITDA $4.6M (+92% YoY); net cash from operations $3.1M.","Balance sheet: cash $30.0M, long-term debt $26.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":67453787.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":903863863.8497277,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}